RNA interference (RNAi) is a posttranscriptional gene-silencing event in which short double-stranded RNA (siR-NA) degrades target mRNA. Because of its potent and highly speciˆc gene-silencing eŠect, RNAi is expected to be used in the treatment of various diseases. Cancer is one of the major targets of RNAi-based therapy, because silencing oncogenes or other genes contributing to tumor progression can be target genes for RNAi. The delivery of RNAi eŠector to target cells is one of the key factors determining therapeutic e‹cacy, because gene silencing is limited to cells reached by RNAi eŠectors. Tumor cell lines stably expressing reporter genes were conˆrmed to be eŠective in sensitively and quantitatively evaluating RNAi eŠects in tumor cells in vitro and in vivo. Quantitative analyses of the gene-silencing eŠect revealed that short-hairpin RNA expressing plasmid DNA (pshRNA) has more durable eŠects than siRNA. Intratumoral injection of RNAi eŠectors was eŠective in suppressing target gene expression in tumor cells, and silencing of b-catenin or hypoxia-inducible factor-1a (HIF-1a) signiˆcantly inhibited tumor growth. RNAi eŠectors were successfully delivered to tumor cells colonizing the liver through the vascular route. We found that tumor-bearing liver showed elevated HIF-1a expression in the cells, and the silencing of the expression in normal liver cells is also eŠective in inhibiting metastatic tumor growth. These results indicate the possibility of RNAi-based cancer therapy.
Because of its highly potent and speciˆc gene silencing eŠect, RNAi is expected to be applied to cancer therapy. To perform RNAi-based therapy, siRNA or pshRNA should be delivered to the target cells because the RNAi eŠect is limited in the cells that received RNAi eŠectors. 
